China Resources Double-Crane Pharmaceutical's subsidiary Alpha Calcitriol Soft Capsules received a drug registration certificate.

China Resources Double-Crane Pharmaceutical (600062.SH) announced that its wholly-owned subsidiary, Beijing Wan Hui Shuanghe Pharmaceutical Co., Ltd. (referred to as "Wan Hui Shuanghe"), has received the "Drug Registration Certificate" for Alfacalcidol soft capsules issued by the National Medical Products Administration. Alfacalcidol soft capsules are used for the treatment of calcium metabolic disorders caused by insufficient endogenous production of 1,25-dihydroxyvitamin D3. This includes renal osteodystrophy, postoperative or idiopathic hypoparathyroidism, pseudo-hypoparathyroidism, as adjunctive therapy for tertiary hyperparathyroidism, anti-vitamin D rickets or osteomalacia, vitamin D-dependent rickets, neonatal hypocalcemia or rickets, calcium malabsorption syndrome, osteoporosis, malabsorption and nutritional rickets, and osteomalacia.